Here are three things to know:
1. Dr. Alwyn Jones, a consultant orthopedic spinal surgeon at Spire Cardiff Hospital in the United Kingdom, implanted MagnetOs in the spines of five patients requiring spinal fusion in 2017.
2. Major takeaways from the case studies include:
- MagnetOs Granules were well-tolerated and no device-related adverse events were reported
- MagnetOs Granules were easy to apply as a standalone graft, when mixed with bone marrow aspirate or local bone
- Resorption and remodeling of MagnetOs Granules was evident from as early as three months after implantation
- The granules promoted spinal fusion in a mixed patient cohort when implanted using five different surgical approaches
3. MagnetOs is a bone graft substitute comprised of biphasic calcium phosphate with a submicron surface topography intended to direct bone formation after implantation.
More articles on biologics:
Wright Medical wins premarket approval for biologic alternative — 6 insights
New study will compare Kuros Biosciences’ MagnetOs, autograft for spinal fusion: 3 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
